Complications and continuation rates associated with 2 types of long-acting contraception

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective We sought to compare complication and continuation rates of the levonorgestrel intrauterine system (LNG-IUS) with the subdermal etonogestrel (ENG) implant across the United States among girls and women 15-44 years of age. Study Design A retrospective study of health insurance claims records from 2007 through 2011 identified a cohort of women who had LNG-IUS (n = 79,920) or ENG implants (n = 7374) inserted and had insurance coverage for 12 months postinsertion. Claims for complications were examined 12 months after insertion, or until removal of either device within each of 3 age groups. Results After its introduction in 2007, the frequency of ENG implants increased each year and almost a third of all insertions were in teenagers. However, among women 24 years old who had delivered an infant in the prior 8 weeks, a LNG-IUS was more likely to be inserted than an ENG implant (P <.05). The most frequent complications with both methods were related to abnormal menstruation, which was more likely to occur among ENG implant users. Overall, 83-88% of the entire sample used their chosen method for at least 12 months. The odds of continuation were similar for both methods among teenagers, but ENG implants were more likely to be removed prematurely among women 20-24 years old (odds ratio, 1.21; 95% confidence interval, 1.06-1.39) and 25-44 years old (odds ratio, 1.49; 95% confidence interval, 1.35-1.64). Conclusion Both of these long-acting contraceptive methods are well tolerated among women of all ages, and demonstrate high continuation rates.

Original languageEnglish (US)
Pages (from-to)761.e1-761.e8
JournalAmerican Journal of Obstetrics and Gynecology
Volume212
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Contraception
Levonorgestrel
Odds Ratio
Confidence Intervals
Device Removal
Insurance Coverage
Menstruation
Health Insurance
etonogestrel
Retrospective Studies
Age Groups

Keywords

  • etonogestrel implant
  • intrauterine device
  • levonorgestrel intrauterine systems
  • long-acting reversible contraception

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Complications and continuation rates associated with 2 types of long-acting contraception. / Berenson, Abbey; Tan, Alai; Hirth, Jacqueline.

In: American Journal of Obstetrics and Gynecology, Vol. 212, No. 6, 01.06.2015, p. 761.e1-761.e8.

Research output: Contribution to journalArticle

@article{d5c1d7162a7e4083a9dfed5cc1293ee1,
title = "Complications and continuation rates associated with 2 types of long-acting contraception",
abstract = "Objective We sought to compare complication and continuation rates of the levonorgestrel intrauterine system (LNG-IUS) with the subdermal etonogestrel (ENG) implant across the United States among girls and women 15-44 years of age. Study Design A retrospective study of health insurance claims records from 2007 through 2011 identified a cohort of women who had LNG-IUS (n = 79,920) or ENG implants (n = 7374) inserted and had insurance coverage for 12 months postinsertion. Claims for complications were examined 12 months after insertion, or until removal of either device within each of 3 age groups. Results After its introduction in 2007, the frequency of ENG implants increased each year and almost a third of all insertions were in teenagers. However, among women 24 years old who had delivered an infant in the prior 8 weeks, a LNG-IUS was more likely to be inserted than an ENG implant (P <.05). The most frequent complications with both methods were related to abnormal menstruation, which was more likely to occur among ENG implant users. Overall, 83-88{\%} of the entire sample used their chosen method for at least 12 months. The odds of continuation were similar for both methods among teenagers, but ENG implants were more likely to be removed prematurely among women 20-24 years old (odds ratio, 1.21; 95{\%} confidence interval, 1.06-1.39) and 25-44 years old (odds ratio, 1.49; 95{\%} confidence interval, 1.35-1.64). Conclusion Both of these long-acting contraceptive methods are well tolerated among women of all ages, and demonstrate high continuation rates.",
keywords = "etonogestrel implant, intrauterine device, levonorgestrel intrauterine systems, long-acting reversible contraception",
author = "Abbey Berenson and Alai Tan and Jacqueline Hirth",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.ajog.2014.12.028",
language = "English (US)",
volume = "212",
pages = "761.e1--761.e8",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Complications and continuation rates associated with 2 types of long-acting contraception

AU - Berenson, Abbey

AU - Tan, Alai

AU - Hirth, Jacqueline

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective We sought to compare complication and continuation rates of the levonorgestrel intrauterine system (LNG-IUS) with the subdermal etonogestrel (ENG) implant across the United States among girls and women 15-44 years of age. Study Design A retrospective study of health insurance claims records from 2007 through 2011 identified a cohort of women who had LNG-IUS (n = 79,920) or ENG implants (n = 7374) inserted and had insurance coverage for 12 months postinsertion. Claims for complications were examined 12 months after insertion, or until removal of either device within each of 3 age groups. Results After its introduction in 2007, the frequency of ENG implants increased each year and almost a third of all insertions were in teenagers. However, among women 24 years old who had delivered an infant in the prior 8 weeks, a LNG-IUS was more likely to be inserted than an ENG implant (P <.05). The most frequent complications with both methods were related to abnormal menstruation, which was more likely to occur among ENG implant users. Overall, 83-88% of the entire sample used their chosen method for at least 12 months. The odds of continuation were similar for both methods among teenagers, but ENG implants were more likely to be removed prematurely among women 20-24 years old (odds ratio, 1.21; 95% confidence interval, 1.06-1.39) and 25-44 years old (odds ratio, 1.49; 95% confidence interval, 1.35-1.64). Conclusion Both of these long-acting contraceptive methods are well tolerated among women of all ages, and demonstrate high continuation rates.

AB - Objective We sought to compare complication and continuation rates of the levonorgestrel intrauterine system (LNG-IUS) with the subdermal etonogestrel (ENG) implant across the United States among girls and women 15-44 years of age. Study Design A retrospective study of health insurance claims records from 2007 through 2011 identified a cohort of women who had LNG-IUS (n = 79,920) or ENG implants (n = 7374) inserted and had insurance coverage for 12 months postinsertion. Claims for complications were examined 12 months after insertion, or until removal of either device within each of 3 age groups. Results After its introduction in 2007, the frequency of ENG implants increased each year and almost a third of all insertions were in teenagers. However, among women 24 years old who had delivered an infant in the prior 8 weeks, a LNG-IUS was more likely to be inserted than an ENG implant (P <.05). The most frequent complications with both methods were related to abnormal menstruation, which was more likely to occur among ENG implant users. Overall, 83-88% of the entire sample used their chosen method for at least 12 months. The odds of continuation were similar for both methods among teenagers, but ENG implants were more likely to be removed prematurely among women 20-24 years old (odds ratio, 1.21; 95% confidence interval, 1.06-1.39) and 25-44 years old (odds ratio, 1.49; 95% confidence interval, 1.35-1.64). Conclusion Both of these long-acting contraceptive methods are well tolerated among women of all ages, and demonstrate high continuation rates.

KW - etonogestrel implant

KW - intrauterine device

KW - levonorgestrel intrauterine systems

KW - long-acting reversible contraception

UR - http://www.scopus.com/inward/record.url?scp=84931572305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931572305&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2014.12.028

DO - 10.1016/j.ajog.2014.12.028

M3 - Article

C2 - 25555662

AN - SCOPUS:84931572305

VL - 212

SP - 761.e1-761.e8

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -